Trastuzumab biosimilar (NeuClone/Serum Institute of India)

曲妥珠单抗生物类似药 (NeuClone/Serum Institute of India)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (NeuClone/Serum Institute of India)

Drug Alias Name曲妥珠单抗生物仿制药 (NeuClone/Serum Institute of India)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeL01XC03